If language is what makes us human, what does it mean now that large language models have gained “metalinguistic” abilities?

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...

The Atom and the Algorithm: Nuclear Energy and AI are Converging to Shape the Future Writers and futurists have long echoed Alvin and Heidi Toffler’s idea that “the future arrives too fast…and in the ...

But there’s a big problem — DeepSeek does not appear to have conducted any predeployment safety testing. There is no mention ...

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

Recursion Pharmaceuticals ( RXRX +1.91%) was in the headlines on Monday, and for the right reason. One of the biotech company ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...

A new NURBS-based algorithm is revolutionizing gridshell design by enabling faster, smoother, and more flexible shape-finding ...